First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05817058 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped As decided by sponsor

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: AFM28

Sponsor

Affimed GmbH